Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials

Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.